tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sara Nik, 4 are a BUY (100%).
Analyst Sara Nik, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 25% that have a potential upside of 29.02% achieved within 50 days.
Sara Nik’s has documented 8 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MBRX, Moleculin Biotech at 24-Mar-2026.
Analyst best performing recommendations are on MBRX (MOLECULIN BIOTECH).
The best stock recommendation documented was for MBRX (MOLECULIN BIOTECH) at 9/10/2025. The price target of $4 was fulfilled within 99 days with a profit of $5.53 (58.03%) receiving and performance score of 5.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 10-Sep-2025
$22
$18.73 (572.78%)
$4
3 months 23 days ago
(24-Mar-2026)
1/2 (50%)
$19.75 (877.78%)
99
Buy Since 09-Jun-2025
$4
$0.73 (22.32%)
$4
1 years 29 days ago
(18-Jun-2025)
2/2 (100%)
$-10.58 (-72.57%)
188
Buy Since 14-Dec-2023
$8
1 years 3 months 22 days ago
(25-Mar-2025)
3/3 (100%)
$-18.5 (-69.81%)
190
Hold Since 25-Mar-2025
$4
$0.73 (22.32%)
1 years 3 months 22 days ago
(25-Mar-2025)
1/1 (100%)
$-24.75 (-86.09%)
268
Buy Since 14-Apr-2021
$30
$26.73 (817.43%)
1 years 11 months 3 days ago
(14-Aug-2024)
3/3 (100%)
$-32.5 (-52.00%)
380
Which stock is Sara Nik is most bullish on?
Which stock is Sara Nik is most reserved on?
What Year was the first public recommendation made by Sara Nik?
